Kathleen Dungan, MD, MPH; Javier Morales, MD, FACP, FACE
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an independent educational grant from Novo Nordisk Inc.
This activity is intended for endocrinologists, primary care providers (PCPs), and other clinicians who manage patients with type 2 diabetes mellitus (T2DM).
After completing this activity, the participant should be better able to:
- Discuss the mechanistic profiles of glucagon-like peptide-1 (GLP-1) receptor agonists, including incretin signaling and glucose homeostasis, potential for cardiovascular benefits, and current and emerging modes of administration with these agents
- Review the evidence for treating patients with T2DM using GLP-1 receptor agonists based on glycemic control, safety signals, and other clinical outcomes
- Intensify antihyperglycemic regimens for T2DM using GLP-1 receptor agonists based on guideline recommendations, individualized glycemic goals, and patient preferences
Individualizing and achieving glycemic targets are critical to optimizing type 2 diabetes mellitus (T2DM) outcomes. Intensive therapy, however, must be balanced with risk, including hypoglycemia, weight gain, common comorbid complications, and adverse cardiovascular events. Improved understanding of disease mechanisms has led to an expanded treatment armamentarium—most notably, a number of new agents within the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class. This CME/CE-accredited Point-of-Care201 3-part series will evaluate recent advances in GLP-RA treatment within T2DM clinical research. It will also provide expert commentary on the mechanistic and clinical profiles of agents in this class, including the latest efficacy and cardiovascular safety data from large-scale clinical trials, new first-in-class modes of administration, the repositioning of GLP-1 RAs in the latest guidelines, and practical considerations for the implementation of GLP-1 RAs within current management and shared decision-making strategies.
- Part 1 - GLP-1 Receptor Agonists in Type 2 Diabetes: Mechanistic Insights and Evolving Treatment Options
- Part 2 - The Latest Evidence Surrounding Current and Emerging GLP-1 Receptor Agonists
- Part 3 - Integrating the Evidence: Utilizing GLP-1 Receptor Agonists in Practice
Kathleen Dungan, MD, MPH
Associate Professor of Medicine
Associate Director of Clinical Services
Division of Endocrinology, Diabetes & Metabolism
Director, Endocrine Clinical Trials
The Ohio State University Wexner Medical Center
Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine
Hempstead, New York
Advanced Internal Medicine Group
East Hills, New York
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Kathleen Dungan, MD, MPH
Consultant/Independent Contractor: Eli Lilly and Company; Grant/Research Support: Eli Lilly and Company, Novo Nordisk A/S, sanofi-aventis U.S. LLC; Honoraria: DKBmed, Elsevier, UpToDate
Javier Morales, MD, FACP, FACE
Consultant/Independent Contractor: Eli Lilly and Company, Mylan N.V., Novo Nordisk A/S; Speakers Bureau: Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Mylan N.V., Novo Nordisk A/S
The following planners and managers reported no financial relationships nor relationships to products or devices they nor their spouses/life partners have with commercial interests related to the content of this CME activity:
Lindsay Borvansky, Kristin Delsi, NP, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour which includes 0.4 hours of pharmacology.
Activity ID #2893E
This activity was planned in accordance with AANP CE Standards and Policies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 1.00
credit type CME/CE
Mechanistic Insights and Evolving Treatment Options